(Q44423669)

English

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

scientific article published on May 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure (English)

1 reference

Europe PubMed Central

2 December 2017

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure (English)

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

author name string

Eleni Maratos

4

1 reference

Europe PubMed Central

2 December 2017

Peter Jenner

5

1 reference

Europe PubMed Central

2 December 2017

Lance A. Smith

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12722161

29 December 2023

Michael J. Jackson

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12722161

29 December 2023

Matthew J. Hansard

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12722161

29 December 2023

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

2 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.10394

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

https://onlinelibrary.wiley.com/doi/full/10.1002/mds.10394

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Movement Disorders

1 reference

Europe PubMed Central

2 December 2017

18

1 reference

Europe PubMed Central

2 December 2017

5

1 reference

Europe PubMed Central

2 December 2017

487-495

1 reference

Europe PubMed Central

2 December 2017

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Levodopa induces dyskinesias in normal squirrel monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10394

21 January 2018

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

12

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

14

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys

18

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

19

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

26

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

31

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

32

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

33

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets

34

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets

35

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

36

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease

39

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.

40

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats

41

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

42

1 reference

10.1002/MDS.10394

https://api.crossref.org/works/10.1002/MDS.10394

29 December 2023

Identifiers

10.1002/MDS.10394

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44423669&oldid=2039533238"